LongevityNext
Autophagy is central to aging biology, but proving target engagement and clinical benefit in humans remains difficult. The piece keeps the focus on evidence, commercial logic, and what…
A measured piece on mTOR, off-label enthusiasm, human evidence, side effects, dosing, and why rapamycin remains both important and unresolved. The piece keeps the focus on evidence, commercial…
Treat reprogramming as the next major therapeutic frontier, but frame the real product as control, delivery, reversibility, and safety rather than simple rejuvenation. The piece keeps the focus…
Few ideas in longevity science remain as intuitively powerful as senolytics. If aging tissues accumulate senescent cells — damaged cells that stop dividing but refuse to die, while…
Few drug classes have moved from endocrinology into so many neighboring territories so quickly. What began as a diabetes story became an obesity story, then a cardiovascular story,…